The SYT-SSX1 fusion transcript showed a non-significant trend toward reduced metastasis-free survival compared to SYT-SSX2 in patients with synovial sarcoma (adjusted HR 1.61).
Cohort (n=64)
No
Does the SYT-SSX1 fusion transcript predict reduced metastasis-free survival and correlate with histologic subtype in synovial sarcoma?
The SYT-SSX1 fusion transcript may be associated with reduced metastasis-free survival and the biphasic histologic subtype in synovial sarcoma.
Effect estimate: HR 1.61 (95% CI 0.80-3.23)
p-value: p=0.183
A case series of 64 synovial sarcomas was characterized for the SYT-SSX fusion transcripts and statistically analysed in order to correlate molecular data with prognosis and morphology. SYT-SSX1 fusion transcript appeared to be an independent, though not reaching statistical significance (P = 0.183), prognostic factor clearly associated with a reduced metastasis-free survival. Regarding the association between transcript type and histologic subtype we found, a borderline P value (P = 0.067) between the SYT-SSX1 transcript and the biphasic subtype which, subsequently expanding the analysis to 70 cases, turned out to be significant. However, we could not confirm the prediction value of the biphasic subtype for the presence of the SYT-SSX1 transcript since in our hands 6 out 33 (18%) biphasic tumours carried the SYT-SSX2 transcript.
Mezzelani et al. (Thu,) conducted a cohort in Synovial Sarcoma (n=64). SYT-SSX1 fusion transcript vs. SYT-SSX2 fusion transcript was evaluated on Metastasis-free survival (HR 1.61, 95% CI 0.80-3.23, p=0.183). The SYT-SSX1 fusion transcript showed a non-significant trend toward reduced metastasis-free survival compared to SYT-SSX2 in patients with synovial sarcoma (adjusted HR 1.61).